department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Erleada · pharmadog

pharmadog
drugs
Erleada

drug

patient view →

apalutamide

Marketedupdated 2mo ago

by $JNJ JOHNSON & JOHNSON

Approved

community read0 votes

indications

investigational

Prostate Cancer

all catalysts(15)

approval · 15

view all 15 catalysts →

News(0)

no news has mentioned this drug yet

brand

Erleada

generic

apalutamide [INN]

indication

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

phase

marketed

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

ERLEADA (APALUTAMIDE) — FDA approval

Data sources

openFDA · ClinicalTrials.gov

last refreshed 31m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 27, 2027

263 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (28)

Jan 14, 2041method-of-use (U-4449)US 11723898
Jan 14, 2041method-of-use (U-4449)US 11723898
Jan 30, 2040method-of-use (U-3901)US 11963952
Jan 30, 2040method-of-use (U-3901)US 11963952
Jan 30, 2040method-of-use (U-4201)US 12303497
Jan 30, 2040method-of-use (U-4201)US 12303497
Apr 30, 2038method-of-use (U-3012)US 10702508
Apr 30, 2038method-of-use (U-3012)US 10702508
Dec 3, 2035formulationUS 12303493
Dec 3, 2035formulationUS 12303493
Sep 23, 2033method-of-use (U-3013)US 10849888
Sep 23, 2033method-of-use (U-3013)US 10849888
Sep 23, 2033method-of-use (U-2237)US 9884054
Sep 23, 2033method-of-use (U-2237)US 9884054
Sep 23, 2033method-of-use (U-2381)US RE49353
Sep 23, 2033method-of-use (U-2381)US RE49353
Sep 23, 2033method-of-use (U-4450)US RE50642
Sep 23, 2033method-of-use (U-4450)US RE50642
Jun 4, 2033compositionUS 9481663
Jun 4, 2033compositionUS 9481663
Sep 15, 2030compositionUS 84455074.2y
Sep 15, 2030compositionUS 84455074.2y
Mar 27, 2027method-of-use (U-2624)US 8802689263d
Mar 27, 2027method-of-use (U-2624)US 8802689263d
Mar 27, 2027compositionUS 9388159263d
Mar 27, 2027compositionUS 9388159263d
Mar 27, 2027formulationUS 9987261263d
Mar 27, 2027formulationUS 9987261263d

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 4

drugERLEADA60 co-mentions · 15 sources
tagApproval60 co-mentions · 15 sources
companyJanssen Biotech Inc30 co-mentions · 15 sources
tagSmall Molecule30 co-mentions · 15 sources

Trials studying apalutamide

phase3An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASactive not recruitingn=1,503
phase1A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Canceractive not recruitingn=19
phase3A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomyactive not recruitingn=2,517
phase2Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.recruitingn=192
phase3An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)active not recruitingn=982
phase3A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Canceractive not recruitingn=1,207
—A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamideactive not recruitingn=504
phase3PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.recruitingn=120

more trials →